Background. The clinical relevance of ultrasensitive human immunodeficiency virus type 1 (HIV-1) genotypic resistance testing in antiretroviral treatment (ART)-experienced individuals remains unknown.
Choosing the right antiretroviral therapy (ART) is one of the most cost-effective actions in medicine [1, 2] . Effective ART provides enormous benefits in health status, survival, and quality of life to people living with human immunodeficiency virus type 1 (HIV-1) [3, 4] . It also delivers important benefits to our society, including virtual elimination of onward HIV-1 transmission in ideal conditions of treatment access and adherence [5, 6] . Antiretroviral drug resistance testing provides key information to clinicians to select the optimal ART for each patient [7] . Surveillance of transmitted and acquired antiretroviral drug resistance is essential for public health policies to control the HIV/AIDS pandemic [8] [9] [10] [11] [12] .
During more than a decade, genotypic HIV-1 drug resistance testing has relied on inferring antiretroviral susceptibility from HIV-1 sequences obtained by Sanger sequencing of plasma viruses. This approach is effective, fast, affordable, and easy to standardize and implement in routine diagnostic laboratories. However, Sanger sequencing only provides a consensus sequence reflecting the most abundant viral variants (>15%-20%) in the HIV-1 population for each patient. Thereby, clinicians miss potentially relevant information on low-frequency drug-resistant (LFDR) HIV when making their treatment choices [13] . Accounting for such additional information could improve ART design and therefore provide further clinical benefits to people living with HIV.
Antiretroviral-experienced subjects with multidrug-resistant HIV-1 are our most difficult-to-treat patients and could highly benefit from more precise resistance evaluations. Failure to suppress viral replication with subsequent salvage ART might result in exhaustion of treatment options and increased mortality [14] . Although data analysing the impact of LFDR HIV and minority CXCR4 viruses on first-line antiretroviral therapy (ART) outcomes has accumulated in recent years [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] , the clinical relevance of ultrasensitive genotyping in treatment-experienced individuals remains largely unexplored.
METHODS

Study Design
This was a retrospective, multicentre, cohort study developed in 4 Spanish HIV tertiary care academic hospitals. The study was registered at Clinicaltrials.gov under the ID: NCT01346878.
Subjects
Study participants were ART-experienced, HIV-1-infected adults who initiated salvage ART including, at least 1 ritonavirboosted protease inhibitor (PI/r), raltegravir (RAL), or etravirine (ETR). Subjects had to have 1 mL of plasma available for genotypic resistance testing with HIV-1 RNA levels ≥5000 copies/mL within 48 weeks before treatment change (baseline).
Data Collection
The demographic and clinical characteristics of study participants, including HIV-1 RNA and CD4+ T-cell counts were obtained from the clinical records of each participating centre and collected in a standardized, curated, and study-dedicated database (TherapyEdge-DeepCheck-HIV, ABL S.A., Luxembourg) centralised at the irsiCaixa AIDS Research Institute. Virological failure was defined as 2 consecutive HIV-1 RNA levels ≥200 copies/mL at least 12 weeks after salvage ART initiation and while subjects were still on the same ART. Due to its retrospective nature, no formal adherence evaluation was available to this study.
Sanger HIV-1 Drug Resistance Testing
The protease (PR) and reverse transcriptase (RT) genes were evaluated in all participants with either the TRUGENE HIV-1 Genotyping Assay (Siemens Healthcare, Spain) or the ViroSeq HIV-1 Genotyping System (Abbott Molecular, Spain). The integrase (IN) gene was sequenced in subjects initiating RAL using an in-house HIV-1 sequencing method (Supplementary methods).
Sequencing
Ultrasensitive HIV-1 genotyping was performed using 2 overlapping amplicons for PR, 5 for the RT and 4 for the IN, which was only sequenced in subjects initiating salvage ART including RAL. 454 sequencing was performed at the irsiCaixa AIDS Research Institute using a 454 GS FLX equipment with Titanium chemistry. According to sequencing strand-dependant error patterns and negative control testing results, only those variants showing frequency values on forward and reverse reads within a 1 log ratio and an overall frequency >0.5% were used for downstream analysis (Supplementary methods).
Genotypic Sensitivity Scores
Separate genotypic sensitivity scores were generated for Sanger (Sanger-GSS) and 454 (454-GSS) information using HIVdb (v6.3.1), ANRS (v2012.09), and REGA (v9.1.0) algorithms, by interfacing with the Stanford HIV-1 Web Service (Sierra, beta v1.0.1). All algorithms were interpreted using a Sensitive/Intermediate/Resistance (S/I/R) scale, corresponding to 1/0.5/0 scores, except for the REGA PI/r S/I/R scores, which were 1.5/0.75/0, respectively. A score of 1 was added per each maraviroc (MRV) and enfuvirtide (T-20) included in the regimen, making the conservative assumption that subjects initiating these drugs had a virus fully susceptible to them. When IN sequences were available, they were used for GSS calculations; otherwise, a score of 1 was added if the subject initiated RAL.
Statistical Analysis
The characteristics of the study population were described overall and according to virological outcomes. Differences in baseline characteristics between subjects with and without virological failure were evaluated for statistical significance using the χ 2 or Fisher exact test for categorical variables and the Mann Whitney rank sum test for continuous variables, as needed. The effect of 454 over Sanger sequencing on GSS categories was described using bubble plots where the diameter of each bubble was proportional to the number of subjects included in each combined category. The overall ability of Sanger and 454-GSS to predict virological failure was compared using by receiver operating characteristic (ROC) curves. Pairwise differences in area under the curve between 454 and Sanger GSS estimations were assessed for statistical significance using the method of Delong, Delong, and Clarke-Pearson [27] . Kaplan Meier curves were then used to describe time to virological failure according to 454 and Sanger GSS categories <3 and ≥3, using HIVdb, ANRS, and REGA algorithms. Statistically significant differences were evaluated using the Log-Rank test. Observations were right-censored if subjects changed the ART regimen received at the time of GSS calculation or if followup was interrupted. Finally, univariate and multivariate Cox proportional hazards models were constructed to evaluate baseline parameters associated with virological failure. The multivariate Cox model was built using covariates achieving a P-value < .05 in the univariate analysis. Statistical analyses were performed using SigmaPlot v12.5 (Systat Software, Inc.) and R software.
Sequence Datasets
Raw 454 sequences were deposited in the NCBI Sequence Read Archive (BioProject PRJNA243019).
RESULTS
Subjects' Selection
The original screening of the participating sites' databases identified 240 individuals potentially fulfilling the inclusion criteria ( Figure 1 ). Twenty-nine individuals were excluded because Figure 1 . Subject disposition. This diagram summarizes the reasons for inclusion/exclusion of subjects in the study and the number of subjects evaluable by the 454 and Sanger sequencing. Subjects were considered evaluable if they fulfilled all inclusion criteria and had a genotypic test that provided complete information in, at least, protease and reverse transcriptase to construct genotypic sensitivity score. *There were 31 subjects with Sanger but no 454 data and 1 subject with 454 but no Sanger data; 100 subjects had both 454 and Sanger data. Abbreviations: GSS, genotypic sensitivity score; HIV-1, human immunodeficiency virus type 1. Abbreviation: ART, antiretroviral therapy.
they were ART-naïve; 37 had baseline HIV-1 RNA levels <5000 copies/mL and 29 additional subjects lacked complete clinical information or follow-up. The remaining 145 subjects fulfilled the inclusion criteria and were sequenced. In 7 subjects, HIV-1 could not be amplified by either sequencing method; 6 additional individuals were excluded due to lack of phylogenetic clustering of Sanger and 454 consensus sequences. This left 132 evaluable subjects, 28 (21%) experiencing virological failure. A GSS could be constructed in 131 individuals using Sanger sequencing and in 101 using 454 sequencing; 100 subjects had both Sanger and 454 GSS estimates available.
Baseline Characteristics
The evaluable subjects were mostly men (72%), of white ethnicity (97%), intravenous drug users (50%), with the previous CDC AIDS C category (71%), prolonged ART experience (median 13.8 years and 13 previous ARV drugs), and low nadir CD4 Table R1 for detailed information on salvage treatments started). The median follow-up after TC was 13.6 months, and the median time between genotypic testing and TC was 1.5 months. The abovementioned characteristics were well balanced between virological outcome groups, except for marginally significant increases in number of ARV drugs exposed to (15 vs 12, P = .078), time between genotypic testing and TC (3.1 vs 1.4 months, P = .080), and recruitment from center 02 (36% vs14%, P = .057) among subjects developing virological failure.
GSS Distribution by Sanger and 454 Sequencing
Median GSS values were 3.0 by Sanger and 454 sequencing, except for the 454-GSS estimation using the HIVdb algorithm, which was 2.5 (Table 1) . Median 454-GSS values were significantly lower and the proportion of subjects with a 454-GSS < 3 significantly higher in subjects developing virological failure than in nonfailures with any of the 3 algorithms (Table 1) ; such differences were not found when GSS calculations were based on Sanger sequencing. In the analysis of 454 vs Sanger GSS categories (Figure 2 ), 69%-73% of subjects retained the same GSS value with both sequencing methods; the most frequent category was GSS = 3 for HIVdb and ANRS, and GSS = 3.5 for REGA. In total, 454 sequencing produced a smaller GSS estimate than Sanger sequencing in 23%-25% of subjects, but led to higher GSS estimates in 4%-7% of individuals. Reasons for the latter observation were further explored (Supplementary results, Table R2 ).
Ability of Sanger and 454 Sequencing GSS Estimates to Predict Virological Failure
GSS estimates calculated with 454 sequencing achieved higher diagnostic accuracy than those calculated with Sanger sequencing regardless of the algorithm used ( Figure 3 ). Pairwise differences in the area under the curve in the receiver operating characteristic curves between 454 and Sanger sequencing were: 0.69 vs 0.60 (P = .029) for HIVdb; 0.72 vs 0.60 (P = .005) for ANRS, and 0.67 vs 0.60 (P = .008) for REGA.
Survival Analysis of Time to Virological Failure
Overall, 28/132 subjects (21%) developed protocol defined virological failure, which mostly occurred during the first year after TC (Figure 4 for HIVdb; Supplementary Results Figure R1 for ANRS and REGA). Time to virological failure was significantly shorter for subjects with a 454-GSS < 3 than in those with a 454-GSS ≥ 3 (Log-rank P-values: .003 for HIVdb, .004 for ANRS and < .001 for REGA). Conversely, time to virological failure was not significantly different between Sanger GSS estimates <3 or ≥3. In a sensitivity analysis using combined Sanger and 454-GSS categories (Supplementary Results Figure R2 ), categories including a 454-GSS < 3 were associated with shorter time to virological failure regardless of their Sanger-GSS. However, this analysis was underpowered to address statistical significance.
Cox Regression Models of Risk of Virological Failure
Baseline factors associated with virological failure in the univariate Cox analysis (Table 2) 
DISCUSSION
This study found that genotypic sensitivity scores based on ultrasensitive HIV-1 genotyping discriminated salvage ART outcomes better than those relying on Sanger sequencing. Our findings were consistent across resistance interpretation algorithms in ROC curve and survival analyses, including multivariate Cox regression, where having <3 active drugs in the salvage regimen by 454 sequencing was a strong independent predictor of subsequent virological failure. Ultrasensitive genotyping reduced the GSS estimate achieved by Sanger sequencing in approximately one quarter of subjects, suggesting that at least one quarter of treatment-experienced subjects requiring salvage ART might benefit from a genotyping approach with increased sensitivity. Our observations thus suggest that ultrasensitive HIV-1 genotyping might indeed be helpful to optimizing salvage ART in subjects infected with multidrug-resistant HIV-1.
To our knowledge, this is the first cohort study addressing the clinical value of ultrasensitive genotyping in ART-experienced subjects. Strict selection criteria and several rounds of database curation were put in place to minimize biases and confounders as much as possible. Rather than evaluating discrete sets of mutations, we used GSS to assess the overall virus susceptibility to salvage ART. Multivariate Cox regression models attempted to P-values were obtained with the χ 2 or Fisher tests for categorical data, and the Mann-Whitney rank sum test for continuous data). The total number of subjects was 132, except for the following variables (*): previous CDC category C (n = 119); Nadir CD4 + T cells and CD4 + T cells at TC (n = 131); all Sanger-GSS categories (n = 131, 28 with and 103 without virological failure), and all 454-GSS categories (n = 101, 22 with and 79 without virological failure).
Abbreviations: ARV, antiretroviral; CDC, centers for disease control and prevention; HIV, human immunodeficiency virus; HTS, heterosexual; IQR, 25%-75% interquartile range; IVDU, intravenous drug use; MSM, men who have sex with men; PI/r, ritonavir-boosted protease inhibitor; Sanger-GSS, genotypic susceptibility score calculated from Sanger sequencing data; 454-GSS, genotypic susceptibility score calculated from 454 sequencing data; TC, treatment change. Figure 2 . Genotypic sensitivity scores (GSS) by 454 vs Sanger sequencing. Bubble plots of the combined Sanger and 454 sequencing GSS categories for the 100 subjects with both genotypic data types available. Separate graphs are shown for each HIVdb (v6.3.1), ANRS (v2012.09), and REGA (v9.1.0) algorithms. The diameter of each bubble is proportional to the number of subjects included in the corresponding combined GSS category. In bubbles centred on the diagonal line (overall number of subjects shown on top of the diagonal line), Sanger and 454 sequencing produced the same GSS estimates. In bubbles below the diagonal line (overall number of subjects shown on the lower-right corner), 454 sequencing produced a smaller GSS estimate than Sanger sequencing. In bubbles above the diagonal line (overall no. of subjects shown on the upper-left corner), 454 sequencing produced a larger GSS estimate than Sanger sequencing.
control for the effect of the most common potential confounders, such as HIV-1 RNA levels of CD4 + T-cell counts. We also excluded all subjects with any suspicion of nonadherence by clinical records. However, no formal adherence data were available in this study due to its retrospective nature. Previous studies in antiretroviral-naive subjects showed that both the presence of LFDR HIV-1 and suboptimal adherence were independent risk factors for virological failure to first-line NNRTI ART but also potentiated each other's effects on virologic failure [28] . It may be easier to detect LFDR HIV-1 in non-fully adherent individuals due to lower degrees of fixation of mutants in the viral population [29] ; in practice, this could also help clinicians make better-informed ART choices in non-fully adherent subjects. Our findings are thus encouraging and set a basis for future confirmatory prospective evaluations but should be interpreted with caution. Importantly, our study highlights a number of issues that should be addressed by future research.
One circular problem with interpreting ultrasensitive drug resistance data is that, on one hand, all genotypic interpretation algorithms, including those used in our study, have been developed and validated using Sanger sequencing data, but, on the other hand, next-generation sequencing (NGS) data are needed to develop new algorithms or adapt the existing ones to address minority variant information. It is unknown, for example, how variant frequency data should be treated in these algorithms, whether mutations should be weighted according to their frequency in the virus population, or how such weights should be established. Answering these questions would require much larger data sets with, possibly, thousands of treatment change episodes.
After balancing the advantages and limitations of the different possible approaches to mutational data interpretation, we deliberately chose using the HIVdb, ANRS, and REGA algorithms "as they are," and treat LFDR variants as binary variables ( presence vs absence) disregarding their frequency in the population. Our assumption was that LFDR variants detected at HIV-1 RNA levels ≥5000 copies/mL represented a clinically meaningful amount of viruses. Such assumption is partially supported by previous studies in ART-naive subjects, which showed that even the presence of 10 copies/mL of mutant virus had a significant impact on clinical outcomes to firstline NNRTI ART. In contrast with studies in naive individuals, we did not use mutational load information to evaluate outcomes because, in our population, subjects had multiple mutations in different genes as well as an extensive treatment history, and no theoretical framework is available yet to properly analyse that information. Nevertheless, our simplified approach was able to improve Sanger-based GSS predictions, suggesting that (a) a reductionist approach to ultrasensitive HIV-1 genotyping may already provide benefits to patients, and (b) such strategy can potentially be improved, albeit through nontrivial methodological approaches.
The small sample size of our study only allowed us to test GSS categories above and below 3. Although this cutoff is meaningful from a clinical perspective-all HIV management guidelines recommend treating patients with at least 3 active drugs-the study was not powered enough to assess GSS strata with increased granularity. Similarly, we were not able to assess the effect of specific antiretroviral drugs other than accounting for their presence in the regimen in the Cox analysis. Also, historical genotypes, which have been shown to correlate with 454 data in previous studies [30] , were not available to us in a consistent manner to enable a direct comparison of their diagnostic performance with that of ultrasensitive HIV-1 genotyping. Although recruitment of virological failures differed by center, this was not an independent predictor of virological failure in the multivariate Cox analysis.
Previous studies have shown that ultrasensitive HIV-1 genotyping is useful for treatment-naive subjects initiating first-line and Sanger categories were statistically significant using the method of Delong, Delong, and Clarke-Pearson [27] , ie, P = .029 for HIVdb; P = .005 for ANRS, and P = .008 for REGA.
NNRTI therapy, women exposed to pMTCT programs including single-dose NVP who require NNRTI ART, and individuals requiring treatment with small-molecule CCR5 antagonists at any stage of the disease [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Our study suggests that deep HIV-1 sequencing is also useful to tailor salvage ART in treatment-experienced subjects. Our observations likely hold for different NGS platforms, which have consistently shown technical equivalence to 454 sequencing in HIV-1 genotyping [31] . Of note, due to our stringent quality criteria for GSS calculation, we could not calculate 454-GSS in almost one quarter of subjects.
Subjects included in this study were highly ART-experienced. We could expect similar findings for salvage ART in earlier stages of the disease, because clinicians would have more antiretroviral options to choose from. Previous studies [29, 32] , for example, showed that LFDR HIV-1 information improved GSS evaluations to drugs like etravirine, which might have an impact on which treatment combinations are chosen for second or third-line ART. Finally, HIV-1 genotyping was performed on subjects with HIV-1 RNA levels >5000 copies/mL, which reduces sampling biases and false-positive mutations. If virological failure occurred at lower HIV-1 RNA levels, NGS would, at least, provide technical noninferiority to Sanger sequencing [33] , although the chance of detecting low-frequency variants would logically decrease if less RNA molecules were sampled.
The technical performance of ultrasensitive HIV-1 genotyping is only one factor determining its applicability in the clinical setting. Cost, workload, and technical complexity of NGS platforms are rapidly decreasing, as throughput, scalability, and automation of workflows and sequence interpretations improve [13] . The field is evolving rapidly, and even diagnostic companies currently supporting Sanger sequencing are adapting routine HIV-1 genotyping to NGS. Continuous decreases in sequencing costs coupled with adequate logistics, including centralised testing of large amounts of samples, might turn HIV-1 genotyping into a more affordable tool for HIV-1 resistance surveillance and clinical management in the coming years, even for resource-limited settings.
In conclusion, our study shows that ultrasensitive HIV-1 genotyping consistently improves GSS-based predictions of virological outcomes of salvage ART relative to Sanger sequencing. Ultrasensitive HIV-1 genotyping could become a useful tool to improve the clinical management of treatment-experienced individuals living with HIV-1. Abbreviations: ARV, antiretroviral; CI, confidence interval; HR, hazard ratio; 454-GSS, genotypic sensitivity score calculated from 454 sequencing data.
